Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 3/20 | 0.44 |
| ▸ | DRD4 | P21917 | 6/20 | 0.44 |
| ▸ | DRD2 | P14416 | 4/20 | 0.44 |
| ▸ | DRD3 | P35462 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14922207 | 0.94 | AURKA (0.43) | KCNH2AURKACDK1CCNB1CDK2 | |
| SCHEMBL13446059 | 0.92 | AURKA (0.42) | KCNH2AURKACDK1CCNB1CDK2 | |
| SCHEMBL8300921 | 0.89 | AURKA (0.43) | KCNH2AURKACDK1CCNB1CDK2 | |
| SCHEMBL8305800 | 0.89 | LMNA (0.49) | AURKACDK1CCNB1CDK2AURKB | |
| SCHEMBL12582671 | 0.88 | AURKA (0.47) | DRD4DRD2CYP3A4AURKACDK1 | |
| SCHEMBL12252946 | 0.88 | AURKA (0.44) | AURKACDK1CCNB1CDK2AURKB | |
| SCHEMBL12582585 | 0.88 | AURKA (0.45) | AURKACDK1CCNB1CDK2AURKB | |
| SCHEMBL13545033 | 0.87 | AURKA (0.43) | AURKACDK1CCNB1CDK2AURKB | |
| SCHEMBL12303277 | 0.87 | AURKA (0.43) | KCNH2AURKACDK1CCNB1CDK2 | |
| SCHEMBL12252754 | 0.87 | AURKA (0.48) | CYP3A4AURKACDK1CCNB1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883790-B2 | Pharmaceutical combinations | ASTEX THERAPEUTICS LIMITED (GB) | 2014-11-11 | — | — | US | disclosed |
| US-8883790-B2 | Pharmaceutical combinations | ASTEX THERAPEUTICS LIMITED (GB) | 2014-11-11 | — | — | US | disclosed |
| EP-2305250-B1 | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2014-03-26 | — | — | EP | disclosed |
| US-20140010892-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2014-01-09 | — | — | US | disclosed |
| US-20140010892-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2014-01-09 | — | — | US | disclosed |
| EP-1648426-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2014-01-08 | — | — | EP | disclosed |
| US-8399442-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| US-8399442-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| US-20110224203-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-09-15 | — | — | US | disclosed |
| US-20110224203-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-09-15 | — | — | US | disclosed |
| US-7977477-B2 | Benzimidazole derivatives and their use as protein kinase inhibitors | ASTEX THERAPEUTICS, LIMITED (GB) | 2011-07-12 | — | — | US | disclosed |
| US-7977477-B2 | Benzimidazole derivatives and their use as protein kinase inhibitors | ASTEX THERAPEUTICS, LIMITED (GB) | 2011-07-12 | — | — | US | disclosed |
| US-20110159111-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-06-30 | — | — | US | disclosed |
| US-20110159111-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-06-30 | — | — | US | disclosed |
| EP-2305250-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Astex Therapeutics Limited (GB) | 2011-04-06 | — | — | EP | disclosed |
| US-20100004232-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (UK) | 2010-01-07 | — | — | US | disclosed |
| US-20100004232-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (UK) | 2010-01-07 | — | — | US | disclosed |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUCTICS, LIMITED (US) | 2007-06-14 | — | — | US | disclosed |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUCTICS, LIMITED (US) | 2007-06-14 | — | — | US | disclosed |
| WO-2005002552-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224203-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | CDK1, CCNI, CDK2 | HTR4 4145/4885DRD4 4809/4885DRD2 4873/4885 |
| US-20100004232-A1 | Pharmaceutical Compounds | ERBB3, ABL1, RET | HTR4 2986/4885DRD4 3966/4885DRD2 4104/4885 |
| US-20140010892-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | CDK1, CCNI, CDK2 | HTR4 4145/4885DRD4 4809/4885DRD2 4873/4885 |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | CDK1, AURKA, CDK2 | HTR4 4052/4885DRD4 4413/4885DRD2 4666/4885 |
| US-20110159111-A1 | PHARMACEUTICAL COMBINATIONS | SLC10A1, CYP11B2, SDHB | HTR4 1919/4885DRD4 3432/4885DRD2 3608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.